Alerts
COVID-19 update
See our updated visitor policy, which allows 1 visitor per patient during exams only and includes masking for all. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

A Randomized Phase II study of Brentuximab Vedotin NSC 749710 and Crizotinib NSC 749005 in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma ALCL IND 117117

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT01979536

Study #:
CMH - ANHL12P1

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT01979536

View Complete Trial Details & Eligibility at ClinicalTrials.gov